Karyopharm Gains After Changes to Late-stage Trial

Seeking Alpha14:12 ET

H.C. Wainwright Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Maintains Target Price $7

Moomoo News12:31 ET · Ratings

Earnings Preview: KPTI to Report Financial Results Pre-market on November 05

Moomoo NewsOct 31 09:45 ET

Karyopharm Therapeutics Announced That, Following FDA Feedback, The Company Will Be Replacing TSS50, One Of The Co-primary Endpoints In The Phase 3 SENTRY Trial With Abs-TSS

BenzingaOct 31 07:43 ET

Express News | Karyopharm Therapeutics Inc - Sentry Trial SAMPLE Size Increased to Approximately 350 Patients

ReutersOct 31 07:30 ET

Express News | Karyopharm Therapeutics Inc - Spleen Volume Response Rate ≥ 35% (Svr35) Remains Co-Primary Endpoint

ReutersOct 31 07:30 ET